Levodopa in the treatment of Parkinson's disease

European Journal of Neurology

Volumn 16, Issue 9, 2009, Pages 982-989

  Schapira, A H V ^a   Emre, M ^b   Jenner, P ^c   Poewe, W ^d  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b ISTANBUL UNIVERSITY   (Turkey)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Catechol O methyl transferase inhibitor; Dopamine; Dopamine agonist; Levodopa; Monoamine oxidase B inhibitor; Parkinson's disease

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; PLACEBO; ROPINIROLE; TOLCAPONE;

BEHAVIOR DISORDER; DIARRHEA; DNA DAMAGE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSKINESIA; GASTROSTOMY; HALF LIFE TIME; HALLUCINATION; HUMAN; LIVER TOXICITY; LONG TERM CARE; MOTOR PERFORMANCE; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOMNOLENCE;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 68849113184     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02697.x     Document Type: Review

References (79)

1. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995 142 : 820 827.
2. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999 52 : 1214 1220.
3. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001 8 : 95 100.
4. Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000 69 : 584 589.
5. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006 59 : 559 562.
6. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007 64 : 1083 1088.
7. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004 351 : 2498 2508.
8. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2008 24 : 514 550.
9. Schapira AH. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov Disord 2008 23 (Suppl. 3 S515 S520.
10. Adams RN, Murrill E, McCreery R, Blank L, Karolczak M. 6-Hydroxydopamine, a new oxidation mechanism. Eur J Pharmacol 1972 17 : 287 292.
11. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978 14 : 633 643.
12. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 1976 19 : 37 40.
13. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992 593 : 343 346.
14. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982 33 : 305 310.
15. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992 142 : 128 130.
16. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994 36 : 348 355.
17. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975 32 : 114 118.
18. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985 58 : 343 346.
19. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991 101 : 198 203.
20. Schapira AH. Oxidative stress in Parkinson's disease. Neuropathol Appl Neurobiol 1995 21 : 3 9.
21. Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia de YJ. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport 1996 7 : 441 445.
22. Owen AD, Schapira AH, Jenner P, Marsden CD. Oxidative stress and Parkinson's disease. Ann N Y Acad Sci 1996 786 : 217 223.
23. Hoyt KR, Reynolds IJ, Hastings TG. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp Neurol 1997 143 : 269 281.
24. Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E. Levodopa induces apoptosis in cultured neuronal cells - a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 1997 12 : 17 23.
25. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993 61 : 1470 1478.
26. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997 69 : 1398 1408.
27. Clement MV, Long LH, Ramalingam J, Halliwell B. The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 2002 81 : 414 421.
28. Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991 29 : 556 559.
29. Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia de YJ. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 1997 104 : 317 328.
30. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989 1 : 1269.
31. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990 54 : 823 827.
32. Ben-Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995 64 : 718 723.
33. Dagani F, Ferrari R, Anderson JJ, Chase TN. L-dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria. Mov Disord 1991 6 : 315 319.
34. Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990 55 : 2142 2145.
35. Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994 3 : 197 204.
36. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997 69 : 1196 1203.
37. Zhang J, Perry G, Smith MA, et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999 154 : 1423 1429.
38. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994 63 : 1987 1990.
39. Ziv I, Melamed E, Nardi N, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994 170 : 136 140.
40. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest 1995 95 : 2458 2464.
41. Hefti F, Melamed E, Jag B, Wurtman RJ. Long term administration of Levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981 21 : 1194 1195.
42. Ferrario JE, Taravini IR, Mourlevat S, et al. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J Neurochem 2004 90 : 1348 1358.
43. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984 43 : 990 993.
44. Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 2002 109 : 53 67.
45. Gu M, Gash MT, Cooper JM, et al. Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord 1997 12 : 418 422.
46. Rajput AH, Fenton M, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997 12 : 634 638.
47. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002 287 : 1653 1661.
48. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003 54 : 93 101.
49. Schapira AH, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 2003 53 (Suppl. 3 S149 S157.
50. Schapira AH. Neuroprotection and dopamine agonists. Neurology 2002 4 (Suppl. 1 S9 S18.
51. Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004 91 : 1075 1081.
52. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001 18 : 389 396.
53. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003 373 : 25 32.
54. Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006 96 : 1315 1321.
55. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004 291 : 358 364.
56. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000 123 : 2297 2305.
57. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. Neurology 1998 51 : 1075 1080.
58. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975 25 : 1144 1148.
59. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990 27 : 18 23.
60. Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987 22 : 535 540.
61. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993 43 : 1698 1703.
62. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991 41 (2 (Pt 1) 202 205.
63. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000 55 : S13 S20.
64. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005 62 : 905 910.
65. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007 22 : 1145 1149.
66. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007 22 : 2409 2417.
67. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994 57 : 903 910.
68. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008 71 : 474 480.
69. Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009 65 : 443 455.
70. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997 42 : 747 755.
71. Bet L, Bareggi SR, Pacei F, Bondiolotti G, Meola G, Schapira AH. Bimodal administration of entacapone in Parkinson's disease patients improves motor control. Eur J Neurol 2008 15 : 268 273.
72. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005 20 : 1502 1507.
73. Russ H, Muller T, Woitalla D, Rahbar A, Hahn J, Kuhn W. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 1999 360 : 719 720. (Pubitemid 30012474)
74. Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Mov Disord 1998 13 : 643 647.
75. Jorga KM. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin Neuropharmacol 1998 21 : S9 S16.
76. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet 1998 352 : 958.
77. Korlipara LV, Cooper JM, Schapira AH. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology 2004 46 : 562 569.
78. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006 6 : 1403 1411.
79. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000 55 (11 Suppl. 4 S13 S20.